Cellectis (Cellectis) Additional Paid-In Capital : $473.33 Mil(As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

Cellectis Additional Paid-In Capital Definition

Cellectis's quarterly additional paid-in capital declined from Mar. 2023 ($608.09 Mil) to Jun. 2023 ($476.22 Mil) but then stayed the same from Jun. 2023 ($476.22 Mil) to Sep. 2023 ($473.33 Mil).

Cellectis's annual additional paid-in capital increased from Dec. 2020 ($872.13 Mil) to Dec. 2021 ($934.70 Mil) but then declined from Dec. 2021 ($934.70 Mil) to Dec. 2022 ($583.12 Mil).

Cellectis Additional Paid-In Capital Historical Data

The historical data trend for Cellectis's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Additional Paid-In Capital Chart

Cellectis Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

828.53

843.48

872.13

934.70

583.12

Cellectis Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Additional Paid-In Capital	Get a 7-Day Free Trial															579.05	583.12	608.09	476.22	473.33

Cellectis Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cellectis Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cellectis's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis (Cellectis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

CMVLF:USA 0WA2:UK ALCLS:France ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.